Toshiko Miyaki

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Successful treatment of histiocytic sarcoma with induction chemotherapy consisting of dose-escalated CHOP plus etoposide and upfront consolidation auto-transplantation

Hideki Tsujimura, Toshiko Miyaki, Shuhei Yamada et al. · International Journal of Hematology · 2014 · 29 citations

Medicine, Oncology, Chemotherapy +2

Impact of sentinel lymph node biopsy by ultrasound-guided core needle biopsy for patients with suspicious node positive breast cancer

Rikiya Nakamura, Naohito Yamamoto, Toshiko Miyaki et al. · Breast Cancer · 2017 · 29 citations

Medicine, Oncology, Pathology +16

Impact of host and histopathological factors on the discrepancies in estrogen receptor, and progesterone receptor, and HER2 status between core needle biopsy and surgically excised tumors

Rikiya Nakamura, Naohito Yamamoto, Nobumitsu Shiina et al. · The Breast · 2015 · 12 citations

Medicine, Oncology, Pathology +14

Neratinib After Trastuzumab-Based Adjuvant Therapy in Patients from Asia with Early Stage HER2-Positive Breast Cancer

Hiroji Iwata, Norikazu Masuda, Sung‐Bae Kim et al. · Future Oncology · 2019 · 12 citations

Medicine, Oncology, Pharmacology +17